Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy

Overview

Journal Tissue Eng Regen Med

Date 2023 Mar 3

PMID 36867402

Authors

Seungyong Shin

Pyunghwajun Lee

Jieun Han

Se-Na Kim

Jaesung Lim

Dae-Hwan Park

Taejong Paik

Junhong Min

Chun Gwon Park

Wooram Park

Affiliations

Soon will be listed here.

Abstract

Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming.

Citing Articles

Nanomaterial-based detection of circulating tumor cells and circulating cancer stem cells for cancer immunotherapy.

Yun Y, Kim S, Lee S, Cho H, Choi J Nano Converg. 2024; 11(1):56.

PMID: 39671082 PMC: 11645384. DOI: 10.1186/s40580-024-00466-x.

Empowering brain tumor management: chimeric antigen receptor macrophage therapy.

Feng F, Shen J, Qi Q, Zhang Y, Ni S Theranostics. 2024; 14(14):5725-5742.

PMID: 39310093 PMC: 11413779. DOI: 10.7150/thno.98290.

A translational framework to DELIVER nanomedicines to the clinic.

Joyce P, Allen C, Alonso M, Ashford M, Bradbury M, Germain M Nat Nanotechnol. 2024; 19(11):1597-1611.

PMID: 39242807 DOI: 10.1038/s41565-024-01754-7.

The next frontier in immunotherapy: potential and challenges of CAR-macrophages.

Li J, Chen P, Ma W Exp Hematol Oncol. 2024; 13(1):76.

PMID: 39103972 PMC: 11302330. DOI: 10.1186/s40164-024-00549-9.

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.

Bui T, Mei H, Sang R, Ortega D, Deng W EBioMedicine. 2024; 106:105266.

PMID: 39094262 PMC: 11345408. DOI: 10.1016/j.ebiom.2024.105266.

References

Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H . Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials. 2005; 26(29):5898-906. DOI: 10.1016/j.biomaterials.2005.02.038. View

Guedan S, Calderon H, Posey Jr A, Maus M . Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019; 12:145-156. PMC: 6330382. DOI: 10.1016/j.omtm.2018.12.009. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

Galvan-Pena S, ONeill L . Metabolic reprograming in macrophage polarization. Front Immunol. 2014; 5:420. PMC: 4151090. DOI: 10.3389/fimmu.2014.00420. View

Benner N, Near K, Bachmann M, Contag C, Waymouth R, Wender P . Functional DNA Delivery Enabled by Lipid-Modified Charge-Altering Releasable Transporters (CARTs). Biomacromolecules. 2018; 19(7):2812-2824. PMC: 6542359. DOI: 10.1021/acs.biomac.8b00401. View

Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan W . FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022; 28(9):1759-1764. PMC: 9064878. DOI: 10.1158/1078-0432.CCR-21-3803. View

Sanber K, Savani B, Jain T . Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. Br J Haematol. 2021; 195(5):660-668. DOI: 10.1111/bjh.17544. View

Mehta R, Rezvani K . Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Front Immunol. 2018; 9:283. PMC: 5818392. DOI: 10.3389/fimmu.2018.00283. View

10.

Sanita G, Carrese B, Lamberti A . Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization. Front Mol Biosci. 2020; 7:587012. PMC: 7726445. DOI: 10.3389/fmolb.2020.587012. View

11.

Testa S, Haabeth O, Blake T, Del Castillo T, Czerwinski D, Rajapaksa R . Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. Biomacromolecules. 2022; 23(7):2976-2988. PMC: 10199726. DOI: 10.1021/acs.biomac.2c00469. View

12.

Kang M, Lee S, Kwon M, Byun J, Kim D, Kim C . Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. Adv Mater. 2021; 33(43):e2103258. DOI: 10.1002/adma.202103258. View

13.

Zhou X, Liu X, Huang L . Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Adv Funct Mater. 2021; 31(5). PMC: 7939128. DOI: 10.1002/adfm.202006220. View

14.

Yu S, Yi M, Qin S, Wu K . Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019; 18(1):125. PMC: 6701025. DOI: 10.1186/s12943-019-1057-4. View

15.

Depil S, Duchateau P, Grupp S, Mufti G, Poirot L . 'Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020; 19(3):185-199. DOI: 10.1038/s41573-019-0051-2. View

16.

Wilk A, Weidenbacher N, Vergara R, Haabeth O, Levy R, Waymouth R . Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Adv. 2020; 4(17):4244-4255. PMC: 7479957. DOI: 10.1182/bloodadvances.2020002355. View

17.

Mullard A . FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017; 16(10):669. DOI: 10.1038/nrd.2017.196. View

18.

Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y . Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020; 7:193. PMC: 7468194. DOI: 10.3389/fmolb.2020.00193. View

19.

Graham C, Jozwik A, Pepper A, Benjamin R . Allogeneic CAR-T Cells: More than Ease of Access?. Cells. 2018; 7(10). PMC: 6210057. DOI: 10.3390/cells7100155. View

20.

Paul S, Lal G . The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol. 2017; 8:1124. PMC: 5601256. DOI: 10.3389/fimmu.2017.01124. View